Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company devel...
New Patent Issued Covering Treatment Of Neurodegenerative Diseases; Studies To Compare Analogs With Bryostatin In SCI
Maxim Group analyst Jason McCarthy upgrades Synaptogenix (NASDAQ:SNPX) from Hold to Buy and announces $14 price target.
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12016837).pn
Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company devel...
